ARTES joins WAVESCATTER

A con­sor­tium of 5 com­pa­nies and the Fraun­hofer-Insti­tut für Lasertech­nik ILT, aim to devel­op under the name of WAVESCATTER („Winke­lau­flösende Wellen­leit­er-Streulicht­sonde für die Inline-Prozes­s­an­a­lytik“) a new kind of scat­tered light sen­sor for pre­cise inline par­ti­cle analytic.

The project will be fund­ed for a three year peri­od by the Ger­man Fed­er­al Min­istry of Edu­ca­tion and Research (BMBF) in the pro­gram Dig­i­tale Optik«.

Part­ner of the con­sor­tium are:

  • Hell­ma GmbH & Co. KG, Müll­heim (Kon­sor­tialführer)
  • ABS Gesellschaft für Automa­tisierung, Bild­ver­ar­beitung und Soft­ware mbH, Jena
  • ARTES Biotech­nol­o­gy GmbH, Lan­gen­feld (Rhein­land)
  • Light­Fab GmbH, Aachen
  • HiTec Zang GmbH, Herzogenrath.

 

PR in Ger­man language:

Mit Photonen im Trüben messen

Vielfältige chemis­che und biotech­nol­o­gis­che Prozesse sind mit dem Entste­hen, dem Wach­s­tum oder der Verän­derung von Par­tikeln ver­bun­den. Eine detail­lierte Beobach­tung von Par­tikel­größe und Par­tike­lan­zahl im laufend­en Prozess ohne zeit- und arbeit­saufwändi­ge Probe­nent­nahme soll die Überwachung und Steuerung solch­er Prozesse in Echtzeit zukün­ftig vere­in­fachen oder über­haupt erst ermöglichen. Im Pro­jekt »WAVESCATTER« haben sich dazu vier Unternehmen und das Fraun­hofer-Insti­tut für Lasertech­nik ILT zusam­mengeschlossen. Ziel ist die Entwick­lung ein­er winke­lau­flösenden Wellen­leit­er-Streulicht­sonde für die präzise Inline-Partikelanalytik.

Wirk­stoffe für Medika­mente wer­den heute zum großen Teil durch spezielle Mikroor­gan­is­men in Biore­ak­toren pro­duziert, wo die Wach­s­tum­sprozesse von beson­der­er Bedeu­tung sind. Die Mikrobenkul­tur wird zusam­men mit ein­er geeigneten Nährlö­sung in den Biore­ak­tor gebracht, ver­mehrt sich dort und pro­duziert die gewün­schte Sub­stanz wie z.B. Insulin, den Leben­sret­ter für Dia­betik­er. Die Mikrobenkul­tur im Biore­ak­tor darf auf keinen Fall mit anderen Mikroor­gan­is­men verun­reinigt wer­den. Dies gelingt am besten, wenn der Reak­tor her­metisch abgeschlossen wird, bis der Pro­duk­tion­sprozess been­det ist. Die Her­aus­forderung liegt in der ständi­gen Überwachung des Prozess­es für einen opti­malen Ablauf, um beispiel­sweise die Nährstof­fzu­gabe an das Wach­s­tumsver­hal­ten der Mikroor­gan­is­men anzu­passen. Eine regelmäßige Proben­nahme mit nach­fol­gen­der Offline-Analyse der Mikrobenkul­tur ist nicht nur arbeits- und zeit­in­ten­siv, son­dern stellt auch eine mögliche Kon­t­a­m­i­na­tion­squelle für den Biore­ak­tor dar. Bis­lang wer­den Proben aus dem Reak­tor ent­nom­men und verdün­nt, um z.B. die Größen­verteilung und Anzahldichte der Mikroor­gan­is­men messen zu kön­nen. Mit der im WAVESCATTER Pro­jekt anvisierten Tech­nolo­gie wird eine inline-fähige Par­tike­l­an­a­lytik entwick­elt, die ohne Proben­verdün­nung auch in optisch dicht­en Lösun­gen Par­tikel­größen zwis­chen weni­gen 10 nm und mehreren µm in Echtzeit bes­timm­bar macht. Dadurch wer­den völ­lig neue Möglichkeit­en zur rück­gekop­pel­ten Überwachung und Steuerung von chemis­chen und biotech­nol­o­gis­chen Pro­duk­tion­sprozessen ermöglicht. Eine Kon­t­a­m­i­na­tion des Fer­menters durch uner­wün­schte Frem­dor­gan­is­men kann frühzeit­ig erkan­nt wer­den. Qual­itätssicherung und Prozes­saus­beute kön­nen so verbessert wer­den. Damit die Probe­nent­nahme aus einem Biore­ak­tor nicht mehr notwendig ist, hat sich das Kon­sor­tium in diesem Ver­bund­pro­jekt zusam­menge­fun­den. Ziel ist die Entwick­lung ein­er optis­chen Tauch­sonde, welch­er durch eine winke­laufgelöste Streulichtmes­sung die Größen­verteilung von Par­tikeln z.B. in Biofer­mentern bes­tim­men kann. Die Licht­führung in der Sonde erfol­gt mit Hil­fe von Wellen­leit­ern, die Licht­de­tek­tion mit ein­er CCD / CMOS Zeile. Aus dem winke­laufgelösten Streulichtsig­nal kön­nen über die Par­tikel­größen­verteilung Infor­ma­tio­nen zu Zell­größe und Teilchen­zahldichte im Inneren des Biore­ak­tors gewon­nen und zur Prozesss­teuerung ver­wen­det wer­den. Eine Fremdbe­siedelung durch uner­wün­schte Mikroor­gan­is­men kann frühzeit­ig erkan­nt wer­den. Per­spek­tivisch ist auch die Ermit­tlung von wichti­gen zell­bi­ol­o­gis­chen Para­me­tern möglich (Lebend- / Totzel­lun­ter­schei­dung, Erken­nung von intrazel­lulären Inklusionskörpern).

Nach erfol­gre­ichem Pro­jek­tab­schluss ste­ht der Prozes­s­an­a­lytik in den Bere­ichen Arzneimit­tel­her­stel­lung und Lebens­mit­tel­pro­duk­tion ein neues Werkzeug zur Ver­fü­gung, mit dem Prozess­pa­ra­me­ter ein­fach­er, flex­i­bler und umfassender in Echtzeit und ohne Probe­nahme erfasst wer­den kön­nen. Weit­ere Ein­satzge­bi­ete kön­nen chemis­che Poly­meri­sa­tion­sreak­tio­nen, Kristalli­sa­tio­nen oder Dis­per­sion­sprozesse sein.

Das Pro­jekt „Winke­lau­flösende Wellen­leit­er-Streulicht­sonde für die Inline-Prozes­s­an­a­lytik — WAVESCATTER“ wird vom BMBF im Rah­men der Pho­tonik Forschung Deutsch­land, Förderini­tia­tive »Dig­i­tale Optik«, unter dem Förderkennze­ichen 13N14176 mit ins­ge­samt 2,1 Mio € gefördert.

BIO International Convention 2017

Meet us at the BIO Inter­na­tion­al Con­ven­tion tak­ing place in San Diego, CA, USA  June 19 ‑22.

Michael Pio­ntek, Man­ag­ing Direc­tor at ARTES, will be present in the One-on-One Part­ner­ing. Con­tact us pre­vi­ous­ly for orga­niz­ing a per­son­al meet­ing or drop us a notice via the part­ner­ing system.

We look for­ward to meet­ing you!

 

www.convention.bio.org/2017

15 Years ARTES Biotechnology

Toady, ARTES has 15 year anniver­sary. In 2002 at May 10th Michael Pio­ntek found­ed ARTES as R&D com­pa­ny, spe­cial­ized in devel­op­ing yeast cell lines for recom­bi­nant pro­tein pro­duc­tion. In 15 years ARTES has posi­tioned itself as val­ued part­ner for the phar­ma­ceu­ti­cal and life sci­ence indus­try and it is now spe­cial­ized in devel­op­ing whole biotech­nol­o­gy pro­duc­tion processes.

ARTES attends European Animal Health Investment Forum

ARTES will head for London’s elite May­fair dis­trict in Feb­ru­ary to take part in the ‘Drag­ons Den’ of vet­eri­nary med­i­cine, the Euro­pean Ani­mal Health Invest­ment Forum.

This will be ARTES’ first par­tic­i­pa­tion in the high pres­tige invest­ment net­work­ing event.

ARTES will be rep­re­sent­ed by its Man­ag­ing Direc­tor, Dr. Michael Pio­ntek, who will be talk­ing in par­tic­u­lar about the devel­op­ment of its inno­v­a­tive pro­pri­etary vac­cine devel­op­ment plat­form, METAVAX®.

METAVAX®advantages

METAVAX® gen­er­ates vac­cines based on the WHO-rec­om­mend­ed yeast organ­ism Hansenu­la poly­mor­pha.

ARTES Biotech­nol­o­gy also has exper­tise in human and ani­mal vac­cine devel­op­ment and is col­lab­o­rat­ing with ani­mal health leader Boehringer Ingel­heim to devel­op  a vac­cine based on Hansenu­la poly­mor­pha expres­sion, com­bined with the METAVAX® platform

Self-adjuvanting vaccines

We look for­ward to attend­ing the Euro­pean Ani­mal Health Invest­ment Forum for the oppor­tu­ni­ty to net­work with CEOs, busi­ness devel­op­ers and sci­en­tists from vet­eri­nary phar­ma­ceu­ti­cal com­pa­nies inter­est­ed in devel­op­ment of high­ly immuno­genic vac­cines,” com­ment­ed Dr. Piontek.

This is a great oppor­tu­ni­ty to find new con­tacts, refresh old ones and show how we have devel­oped an eco­nom­i­cal approach for low-cost mass pro­duc­tion of safe, effec­tive and self-adju­vant­i­ng vac­cines,” said Dr. Piontek.

ARTES will also use the meet­ing to share knowl­edge about its VLP tech­nol­o­gy for anti­gen pre­sen­ta­tion and oth­er vac­cine tech­nolo­gies.  It will also exchange infor­ma­tion on its spe­cial­ist cell lines and process devel­op­ment for bio-phar­ma­ceu­ti­cal products.

Meet us at the Ani­mal Health Invest­ment in Lon­don, 22nd and 23rd Feb­ru­ary, at the Mil­len­ni­um Lon­don May­fair Hotel or con­tact us pre­vi­ous­ly for a per­son­al meet­ing! We look for­ward to meet­ing you!

ARTES and BioSun announce co-development for HPV vaccine

Lan­gen­feld, Ger­many / Tehran, Iran 

ARTES Biotech­nol­o­gy and Bio­Sun Pharmed announced to join forces for the devel­op­ment and man­u­fac­tur­ing of a HPV (human papil­lo­ma virus) vac­cine in Iran.

The agreed long-term col­lab­o­ra­tion involved the strength of both part­ners. ARTES Biotech­nol­o­gy GmbH (ARTES) is spe­cial­ized in cell line and process devel­op­ment of virus like par­ti­cle (VLP) based vac­cines and in tech­nol­o­gy trans­fer for phar­ma­ceu­ti­cal­ly rel­e­vant pro­duc­tion processes. 

Bio­Sun Pharmed Co is involved in the man­u­fac­tur­ing of high qual­i­ty and safe vac­cines and bio­phar­ma­ceu­ti­cal prod­ucts for the domes­tic and inter­na­tion­al markets. 

Human papil­lo­ma virus infec­tion (HPV) is the most com­mon sex­u­al­ly trans­mit­ted infec­tion glob­al­ly. Most peo­ple are infect­ed at some point in their lives. There are approx­i­mate­ly 79 mil­lion men/women active­ly infect­ed with the virus at any point in time. Annu­al­ly, there are 14 mil­lion new­ly diag­nosed cas­es of HPV. HPV infec­tion can cause in warts or pre­can­cer­ous lesions. The pre­can­cer­ous lesions increase the risk of cancer.

In 2012, about 270,000 women died from cer­vi­cal can­cer, more than 85% of these deaths occur­ring in low and mid­dle income countries.

We are extreme­ly delight­ed about the mutu­al­ly agreed col­lab­o­ra­tion. This agree­ment is the next step in ARTES’ strat­e­gy to devel­op from a ser­vice provider for process devel­op­ment to a part­ner for full phar­ma­ceu­ti­cal prod­uct devel­op­ment,” Dr. Michael Pio­ntek, founder and man­ag­ing direc­tor of ARTES Biotechnology.

For the first time, ARTES will be respon­si­ble for process devel­op­ment of API, for­mu­la­tion, qual­i­ty con­trol and sup­ply of pre­clin­i­cal test mate­r­i­al. In addi­tion, ARTES will be engaged in design of the man­u­fac­tur­ing site at Bio­Sun and in selec­tion of third par­ties for GMP manufacturing.

I am real­ly pleased that after tech­ni­cal and com­mer­cial dis­cus­sions, we could final­ly make col­lab­o­ra­tion agree­ment with a well-known and reli­able part­ner for not only pro­duc­ing pre-mas­ter cell banks but also for co-devel­op­ments of our mutu­al inter­est­ed prod­ucts. Our mis­sion is pro­duc­ing high qual­i­ty and afford­able vac­cines and biotech prod­ucts improv­ing health lev­el of com­mu­ni­ty.” Dr. Moham­mad Tagha­vian, man­ag­ing direc­tor of Bio­sun Pharmed.

Finan­cial details of this agree­ment were not disclosed.

Sun Pharma & ICGEB sign exclusive deal on dengue vaccine — ARTES adds experience in VLP development and production

NEW DELHI, India I Octo­ber 19, 2016 

Inter­na­tion­al Cen­tre for Genet­ic Engi­neer­ing and Biotech­nol­o­gy (ICGEB) and Sun Phar­ma today announced their new col­lab­o­ra­tion for devel­op­ment of a dengue vac­cine, tar­get­ed against all the four serotypes of Dengue virus that cause dis­ease in humans. ICGEB has devel­oped a tai­lored recom­bi­nant virus-like-par­ti­cle (VLP) based tetrava­lent dengue vac­cine, con­tain­ing host-recep­tor bind­ing domain of enve­lope pro­tein of all the four DENV serotypes. ICGEB has con­duct­ed pre-clin­i­cal stud­ies over the past sev­en years and devel­oped the exist­ing Know-How and Patents for this dengue vac­cine candidate.

Sun Phar­ma invests over US$ 300 mil­lion annu­al­ly on research and devel­op­ment in phar­ma­ceu­ti­cals and bio­log­ics. The Com­pa­ny will use its in-house exper­tise as well as exper­tise of its Asso­ciate com­pa­ny, ARTES Biotech­nol­o­gy GmbH, in devel­op­ment of dengue vac­cine. ARTES will add their expe­ri­ence and pro­pri­etary know-how in pro­duc­tion of VLP based vac­cines from yeast pro­duc­tion cell lines. Hep‑B and HPV vac­cines devel­oped by ARTES are licensed to sev­er­al com­pa­nies world­wide and a Malar­ia vac­cine pro­gram is spon­sored by PATH (Malar­ia Vac­cine Ini­tia­tive). Tak­en togeth­er, the Com­pa­ny has past expe­ri­ence in devel­op­ment of Hep‑B and Typhoid vac­cines, as well as com­plex vac­cines, such as HPV and Malaria.

 

For the full text, see: http://www.sunpharma.com/media/press-releases

ARTES and Burnet Institute join forces to develop novel hepatitis C vaccine

ARTES Biotech­nol­o­gy and Bur­net Insti­tute announce they have joined forces to devel­op a nov­el, effec­tive vac­cine to pre­vent trans­mis­sion of hepati­tis C virus (HCV).

An HCV vac­cine is urgent­ly need­ed to pre­vent re-infec­tion in peo­ple treat­ed through antivi­ral ther­a­pies and reverse the high glob­al mor­tal­i­ty rates from infec­tion-relat­ed liv­er cir­rho­sis or liv­er can­cer, esti­mat­ed by the World Health Orga­ni­za­tion (WHO) to be more than 500,000 peo­ple each year. More than 130 mil­lion peo­ple glob­al­ly are car­ri­ers of HCV, a blood-borne virus.

The inno­v­a­tive hepati­tis C vac­cine project will com­bine Bur­nets’ pro­pri­etary HepSeeVaxDelta3™ tech­nol­o­gy, devel­oped by Asso­ciate Pro­fes­sor Hei­di Drum­mer and col­leagues, with ARTES’ pro­pri­etary METAVAX® tech­nol­o­gy for the devel­op­ment of chimeric virus-like par­ti­cle (VLP) based vac­cines. The project aims to devel­op a VLP based vac­cine that effi­cient­ly presents HCV anti­gens to pre­vent hepati­tis C infec­tion. The VLPs will present the nov­el, mod­i­fied enve­lope pro­tein (E2) on its sur­face, there­by tar­get­ing the vac­cine to den­drit­ic cells to prime and pre­pare the immune sys­tem to fight against hepati­tis C infection.

Deputy Head of Burnet’s Cen­tre for Bio­med­ical Research and HCV vac­cine team leader, Asso­ciate Pro­fes­sor Drum­mer said HepSeeVaxDelta3™ tech­nol­o­gy over­comes a crit­i­cal lim­i­ta­tion to HCV vac­cine devel­op­ment. “The virus that caus­es HCV has evolved to avoid the immune sys­tem so that in nat­ur­al infec­tion, key immune respons­es are delayed or dis­tract­ed by irrel­e­vant tar­gets on the virus. The same is true for con­ven­tion­al vac­cine plat­forms test­ed pre­vi­ous­ly. The HepSeeVaxDelta3™ com­po­nent of the vac­cine redi­rects the immune response to make anti­bod­ies on the most impor­tant tar­gets that pre­vent infec­tion against the sev­en cir­cu­lat­ing HCV genotypes.”

Man­ag­ing Direc­tor of ARTES, Dr Michael Pio­ntek said his com­pa­ny was excit­ed to join forces with Bur­net Insti­tute to devel­op a much-need­ed vac­cine against hepati­tis C, which is endem­ic in many coun­tries where treat­ment costs are high and HCV pos­es a sig­nif­i­cant bur­den on health­care sys­tems. “Access to diag­no­sis and treat­ment is lim­it­ed, espe­cial­ly in endem­ic coun­tries in Africa and Asia, so there is a strong demand for a safe and low-cost vac­cine to pre­vent hepati­tis C infec­tion. This is in-line with the aim of the WHO to real­ize their hepati­tis C elim­i­na­tion tar­gets. After out-licens­ing process­es for hepati­tis B vac­cine pro­duc­tion world­wide, ARTES is proud to take the next step togeth­er with Bur­net Insti­tute in fight­ing anoth­er life-threat­en­ing hepati­tis infection.”

 

The vac­cine devel­op­ment platform

ARTES’ vac­cine devel­op­ment plat­form METAVAX® in com­bi­na­tion with the expres­sion host Hansenu­la poly­mor­pha (rec­om­mend­ed by the WHO for hepati­tis B vac­cine pro­duc­tion) is the pre­ferred tool for the devel­op­ment of afford­able vac­cines. ARTES’ devel­op­ment plat­form is a unique and very eco­nom­i­cal approach to low-cost mass pro­duc­tion of safe and effec­tive vaccines.

Bur­net Institute’s HepSeeVaxDelta3™ tech­nol­o­gy is devel­oped by re-engi­neer­ing the major HCV viral sur­face pro­tein E2 to pro­duce the nov­el HepSeeVaxDelta3™ vac­cine. HepSeeVaxDelta3™ can gen­er­ate high lev­els of anti­bod­ies that can block repli­ca­tion of all sev­en geno­types of HCV in lab­o­ra­to­ry tests. This major sci­en­tif­ic advance offers the prospect of a sim­ple, uni­ver­sal vac­cine to pre­vent HCV infec­tion worldwide.

ARTES and Biosphere announce collaboration

ARTES Biotech­nol­o­gy, spe­cial­ized in micro­bial cell line and process devel­op­ment for recom­bi­nant pro­tein pro­duc­tion and tech­nol­o­gy provider for high-qual­i­ty biotech­no­log­i­cal process­es, join forces with the well-estab­lished con­tract man­u­fac­tur­ing com­pa­ny Bios­phere. Aim of this pre­ferred coop­er­a­tion is to offer a full range of ser­vices, start­ing from cell line gen­er­a­tion up to indus­tri­al scale man­u­fac­tur­ing in one pack­age. The com­bi­na­tion of the dif­fer­ent exper­tise, know-how and infra­struc­ture of the two com­pa­nies will flow direct­ly into one com­mon offer. This offer address­es cus­tomers who are look­ing for devel­op­ment of enzymes and pro­teins cur­rent­ly applied in the phar­ma­ceu­ti­cal, food and fine chem­i­cal sector.

ARTES offers manufacturing of preclinical samples up to multi-gram scale

ARTES Biotech­nol­o­gy, spe­cial­ized in micro­bial cell line and process devel­op­ment for the phar­ma­ceu­ti­cal indus­try recent­ly expand­ed its ser­vice port­fo­lio and sup­plied sam­ples for pre­clin­i­cal test­ing to a first client.

With the new equipped pilot plant for pro­duc­tion of nonGMP mate­r­i­al, we are now in the posi­tion to pro­vide our clients with high qual­i­ty pre­clin­i­cal test mate­r­i­al in gram amounts”, Michael Weniger Head of Process Devel­op­ment at ARTES stat­ed. “Thanks to our exist­ing expe­ri­ence, instal­la­tion of the plant at ARTES, imple­men­ta­tion of a new process and sup­ply of a batch have been man­aged with­in three months. The chal­lenge in this kind of fast track projects is very often to meet a high qual­i­ty stan­dard”, Weniger point­ed out.

 

For more detailed infor­ma­tion and for an offer please con­tact us.

ARTES and Boehringer Ingelheim Animal Health Announce Collaboration

ARTES Biotech­nol­o­gy, spe­cial­ized in recom­bi­nant pro­tein pro­duc­tion, process and vac­cine devel­op­ment from micro­bial expres­sion sys­tems announces a col­lab­o­ra­tion with the glob­al phar­ma­ceu­ti­cal com­pa­ny Boehringer Ingel­heim Ani­mal Health.

ARTES’ expres­sion sys­tem Hansenu­la poly­mor­pha is the pre­ferred tech­nol­o­gy for afford­able mass vac­ci­na­tion and rec­om­mend­ed by the World Health Orga­ni­za­tion (WHO) for these pur­pos­es. In com­bi­na­tion with ARTESMETAVAX® plat­form, this offers a new, unique and very eco­nom­i­cal approach to low-cost mass pro­duc­tion of safe and effec­tive vac­cines required in the vet­eri­nary field.

This col­lab­o­ra­tion is anoth­er mile­stone in expand­ing our vac­cine devel­op­ment exper­tise”, Michael Pio­ntek, man­ag­ing direc­tor of ARTES stat­ed. “We are more than con­fi­dent that our tech­nol­o­gy plat­form is per­fect­ly suit­ed for the devel­op­ment of safe and cost effi­cient vac­cines that are high­ly rel­e­vant for the vet­eri­nary market.”

Part­ner­ing is a cen­tral part of our strat­e­gy. We are excit­ed about this col­lab­o­ra­tion and the oppor­tu­ni­ty to devel­op more inno­v­a­tive vac­cines for the ani­mal health mar­ket,” says Rolf-Dieter Gün­ther, Head of Glob­al Busi­ness Devel­op­ment and Licens­ing Ani­mal Health for Boehringer Ingelheim.